Nimodipine in catheter flush solutions is associated with reduced vasospasm risk in endovascular stroke treatment.

Authors

Johannes Wischmann, Christian H Nolte, Christoph Riegler, Eberhard Siebert, Tobias Boeckh-Behrens, Silke Wunderlich, Maria Teresa Berndt, Alexander Rattenberger, Friederike Häfner, Verena Hoffmann, Markus A Möhlenbruch, Jan Purrucker, Thomas David Fischer, Lars Kellert, GSR-ET investigators

Published in

Journal of neurointerventional surgery. Sep 11, 2026. Epub Sep 11, 2026.

Abstract

Vasospasm during endovascular treatment (ET) for ischemic stroke is increasingly recognized as a relevant complication associated with worse functional outcomes. The preventive effect of using nimodipine continuously administered intra-arterially in catheter flush solutions (FS) and its impact on functional outcomes are uncertain.
We analyzed data from the German Stroke Registry-Endovascular Treatment, a prospective, multicenter registry including patients treated with ET at 25 centers between June 2015 and December 2023. Center-specific FS protocols were assessed and patients were stratified by use of nimodipine in FS. The primary outcome was vasospasm occurrence. Secondary outcomes included the 90-day modified Rankin Scale (mRS) score. Analyses used inverse probability of treatment weighting (IPTW)-adjusted logistic regression models.
Among 16 583 patients (mean age 73.6 years; 51.7% female), nimodipine-containing FS were used in 7548 patients (45.5%) and FS without nimodipine in 9035 patients (54.5%). Nimodipine-containing FS were associated with lower odds of vasospasm (IPTW-adjusted risk 1.8% vs 4.8%; IPTW-adjusted OR 0.38; 95% CI 0.30 to 0.47; P<0.001). This association was not modified by age (≤60 vs >60 years), stroke type (anterior vs posterior circulation), occlusion type (large vs medium vessel occlusion), or thrombectomy technique (contact aspiration vs stent retriever vs combined/cross-over). Nimodipine-containing FS were associated with higher odds of achieving 90-day mRS 0-1 (IPTW-adjusted OR 1.23; 95% CI 1.13 to 1.34; P<0.001) and mRS 0-2 (IPTW-adjusted OR 1.16; 95% CI 1.08 to 1.25; P<0.001).
Use of nimodipine in catheter FS is associated with a lower risk of vasospasm and improved functional outcomes. Randomized clinical trials are warranted to confirm these findings.
NCT03356392.

PMID:
42728086
Bibliographic data and abstract were imported from PubMed on 12 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.